[4] [5] Appropriate clinical management for patients with comorbid metabolic conditions and problematic alcohol use should include: Comprehensive assessment of alcohol consumption patterns using validated screening tools (AUDIT, AUDIT-C) Referral to addiction medicine specialists or behavioral health providers for evidence-based AUD treatment, especially with red flags such as history of severe withdrawal, seizures, delirium tremens, pregnancy, severe liver disease, or suicidality Consideration of FDA-approved pharmacotherapies for alcohol use disorder (naltrexone, acamprosate, disulfiram) with attention to their specific contraindications [9] [11] If GLP-1 therapy is indicated for diabetes or obesity, close monitoring for changes in alcohol consumption and related behaviors Patient education emphasizing that any effects on alcohol cravings are not established therapeutic benefits Regular follow-up to assess medication adherence, adverse effects, and overall treatment response Patients should never discontinue evidence-based treatments for alcohol use disorder in favor of unproven approaches
I've struggled for years with my weight and can't get covered for the shots which I'm also afraid of
Add fiber gradually if your gut isn't used to it and eventually aim to add a fiber source to every meal
Where appropriate, cognitive behavioural therapy can help to control impulsive eating behaviours, while bariatric surgeries or injectable weight loss drugs might be recommended in urgent cases 13
Safety and efficacy of GLP-1 receptor agonists in type 2 diabetes mellitus with advanced and end-stage kidney disease: a systematic review and meta-analysis
However, a significant challenge in evaluating kidney outcomes lies in the inconsistent definitions of renal endpoints across studies, particularly regarding the thresholds for substantial eGFR decline, which vary from 30% to 57%
)
